ANVISA and replicate designs [Regulatives / Guidelines]

posted by Mauricio Sampaio  – Brazil, 2016-05-18 08:14 (3189 d 18:50 ago) – Posting: # 16319
Views: 11,408

Dear d_labes,

Unfortunatly, until the moment, the ANVISA did not show us a specific guideline published and official to explain how we should to proceed with replicate crossover designs. :-(

The RE 898 from 2003 is old and do not follow the advance of bioequivalence studies.

On the other hand, in some non official meetings, in regulatory terms, ANVISA clarified that accept the use of the statistical method for scaling proposed by the European Agency with the exception that for scaling can only be applied in the cases that the intra-subject coefficient of variation (CV%) exceeds 40% for the originator product.

As we do not have a new regulation, each protocol must be previously submitted to the tech­ni­cal evaluation of Therapeutic Equivalence Coordination (Anvisa) before conducting the bio­equi­va­lence study that you want to consider the scaling.

There are many view points as you can check in "Anvisa's home brewed scaling" posted by Helmut in this forum. Check it out!

During a plan to bioequivalence study for submission in Brazil, frequently I avoid replicate designs. Why? :confused:

Because two reasons:

First, in Brazil we do not have criteria or regulations established and everything can change according a new understanding from ANVISA. Black on white is much better! :yes:

Second, according Helmut's post (ANVISA’s home brewed scaling?), if ANVISA wants 40% as the switching condition, a very little gain in terms of the acceptance range could be observed! :surprised:

Best regards!

Complete thread:

UA Flag
Activity
 Admin contact
23,376 posts in 4,912 threads, 1,662 registered users;
263 visitors (0 registered, 263 guests [including 21 identified bots]).
Forum time: 02:04 CET (Europe/Vienna)

Science is what you know.
Philosophy is what you don’t know.    Bertrand Russell

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5